Market News & Trends
Catalent Biologics Supports DiaMedica's New Treatment
Catalent recently welcomed the news that DiaMedica Therapeutics has received US FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for…
Ritter Pharmaceuticals & Qualigen Announce Merger Agreement
Ritter Pharmaceuticals, Inc. recently reported it has entered into a definitive reverse merger agreement with Qualigen, Inc. as well as expansion of its flagship FastPack diagnostic platform, whereby a wholly owned…..
Aptar Pharma’s Nasal Unidose Device Approved by US FDA
Aptar Pharma recently announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the US FDA as a rescue treatment for….
TEDOR Pharma Adds Frank Sorce as Regional Business Development Director
TEDOR Pharma, a Contract Development and Manufacturing Organization with a 19-year operating history, is pleased to announce Frank Sorce is joining TEDOR as the new…..
Interpace Biosciences Enters Agreement for $20-Million Investment
Interpace Biosciences, Inc. recently announced that it has entered into an agreement for a new Series B Preferred Stock investment of….
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease
Biogen Inc. recently announced an agreement to acquire from Pfizer Inc. a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with…
Codexis & Nestlé Health Science Sign Development Agreement
Codexis, Inc. and Nestlé Health Science have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical….
Adare Pharmaceuticals & NLS Pharmaceutics Collaborate to Develop Controlled-Release Candidates
Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. recently announced a collaboration to develop mazindol (MZD) CR product candidates for the treatment of….
Mereo BioPharma & Oncologie Enter Global Licensing Agreement
Mereo BioPharma Group plc and Oncologie, Inc. recently announced a global license agreement for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently…
OncoCyte Announces Agreement to Acquire Molecular Diagnostics Company
OncoCyte Corporation recently announced it has entered into an agreement to acquire, through a subsidiary, all of the outstanding capital stock of privately-held Insight Genetics,…
Innovative Micro-Infusion Pump From Gerresheimer Subsidiary Sensile Medical for EVER Pharma
Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine, this wearable micro-infusion pump has already been launched in several European countries.…
CytoDyn Files for Breakthrough Therapy Designation With the FDA
CytoDyn Inc. recently announced it has filed for Breakthrough Therapy designation (BTD) with the US FDA for the use of leronlimab as an adjuvant therapy…
Adaptimmune Announces SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Adaptimmune Therapeutics plc recently announced two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. There…
Novavax Granted Fast-Track Designation
Novavax, Inc. recently announced the US FDA has granted Fast-Track Designation for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M, in adults…
Nurix Therapeutics & Sanofi Establish Strategic Collaboration
Nurix Therapeutics, Inc. recently announced a global strategic collaboration with Sanofi to discover, develop, and commercialize a pipeline of innovative targeted protein….
Catalent Completes Purchase of Biologics Fill-Finish & Oral Solid Dose Facility in Anagni, Italy
Catalent recently announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility….
Sebia Enters Development Agreement With Sanofi
Sebia recently announced it is entering into an agreement with Sanofi to develop an in vitro diagnostic (IVD) test that mitigates the potential interference caused by……
WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent
WPD Pharmaceuticals recently announced Wake Forest University received a patent from the United States Patent and Trademark Office (USPTO) for patent 105019210 (issued under application…
Oxford BioTherapeutics Initiates Dose-Escalation Portion of Phase I Clinical Trial
Oxford BioTherapeutics Ltd. recently announced the initiation of the dose-escalation portion of its US Phase 1 program for OBT076, a CD205 targeting antibody-drug conjugate (ADC),…
Zai Lab & Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial
Zai Lab Limited and Novocure recently announced the first patient has been enrolled in a Phase 2 pilot clinical trial evaluating the safety and efficacy…